India Globalization Capital, Inc. (IGC) AI Stock Analysis

India Globalization Capital, Inc. operates two primary business segments: Infrastructure and Life Sciences. The Infrastructure segment leases heavy construction machinery, including motor graders and rollers, and undertakes highway construction contracts. The Life Sciences segment develops cannabinoid-based products and therapies. Its offerings include Hyalolex hemp-based tinctures for anxiety relief and Alzheimer's management, Holief CBD formulations for pain management, and Herbo CBD beauty products. In addition, the company distributes wholesale hemp extracts under Holi Hemp, produces lotions and oils, processes crude oil into hemp extracts, and provides white labeling services across the United States, India, Colombia, and Hong Kong.

The company's five-year revenue CAGR from FY2021 to FY2026 was 5.7%. Annual revenue rose from $397,000 in FY2022 to $1.3M in FY2024, before declining 5.5% to $1.3M in FY2025 and falling 6.7% to $1.2M in FY2026. Gross margin contracted to 29.7% in FY2026 from 48.7% in FY2025. Operating margin remained negative throughout this period, coming in at -860.3% in FY2026, while net income was -$6.5M. For the trailing twelve months ended June 30, 2026, revenue was $1.1M, with quarterly revenue falling 19.2% year-over-year and operating margin reaching -1050.6%.

As of June 30, 2026, the company held $354,000 in cash and short-term investments and total debt of $1.1M, resulting in net debt of $728,000. Shareholders' equity stood at $6.1M against total assets of $9.5M, yielding a debt-to-equity ratio of 0.18 and a current ratio of 0.39. In FY2026, free cash flow was -$6.1M, operating cash flow was -$5.9M, and capital expenditures were $164,000. To fund operations, the company raised $5.2M through share issuance in FY2026, contributing to a 96.5% increase in share count over 5 years.

India Globalization Capital trades at a price-to-sales multiple of 23.0x and an EV-to-EBITDA multiple of 27.3x, compared to medians of 4.1x and 12.0x, respectively, for its US-listed Healthcare peers. Its enterprise value stands at $30.3M relative to a market cap of $25.4M, with a price-to-book ratio of 4.8x. The stock closed at $0.25 on October 16, 2026, down 37.5% over the past year and down 82.9% over five years. Over those same periods, the S&P 500 returned 16.8% and 83.0%.

Wall Street coverage consists of 2 Strong Buy ratings, with 0 Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $6.00, representing a 2300.0% premium over the last close of $0.25. For the current fiscal year ending December 31, 2026, analysts forecast revenue of $958,000 and an EPS of -$0.10. India Globalization Capital missed consensus with 0 EPS beats over the last 4 quarters. The next earnings date is scheduled for November 13, 2026.

This page is an AI-written research summary of India Globalization Capital, Inc. (IGC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IGC income statement, IGC balance sheet, IGC key metrics, IGC analyst forecast, IGC chart. See the IGC stock overview for the latest quote and news.